240 related articles for article (PubMed ID: 12946797)
1. Detection of HER-2/neu gene amplification in breast cancer using a novel polymerase chain reaction/ligase detection reaction technique.
Nathanson DR; Nash GM; Chen B; Gerald W; Paty PB
J Am Coll Surg; 2003 Sep; 197(3):419-25. PubMed ID: 12946797
[TBL] [Abstract][Full Text] [Related]
2. Quantitation of HER-2/neu and c-myc gene amplification in breast carcinoma using fluorescence in situ hybridization.
Persons DL; Borelli KA; Hsu PH
Mod Pathol; 1997 Jul; 10(7):720-7. PubMed ID: 9237184
[TBL] [Abstract][Full Text] [Related]
3. Detection of low level HER-2/neu gene amplification in prostate cancer by fluorescence in situ hybridization.
Liu HL; Gandour-Edwards R; Lara PN; de Vere White R; LaSalle JM
Cancer J; 2001; 7(5):395-403. PubMed ID: 11693898
[TBL] [Abstract][Full Text] [Related]
4. Genetic analysis of HER-2/neu gene amplification in paraffin embedded tumour tissue in women with breast cancer.
Zadrozny M; Smolarz B; Romanowicz-Makowska H; Kozłowska E; Kulig A
Pol J Pathol; 2002; 53(4):189-93. PubMed ID: 12597335
[TBL] [Abstract][Full Text] [Related]
5. The significance of HER-2/neu/c-erbB-2 gene amplification in benign and malignant breast disease.
Supanaranond K; Sukarayodhin S; Tanyakaset M; Balachandra K; Jullaksorn D; Rienkijkarn M; Hoisanka N; Tantivanich S
Southeast Asian J Trop Med Public Health; 1997 Sep; 28(3):631-40. PubMed ID: 9561622
[TBL] [Abstract][Full Text] [Related]
6. Histopathologic characteristics predicting HER-2/neu amplification in breast cancer.
Prati R; Apple SK; He J; Gornbein JA; Chang HR
Breast J; 2005; 11(6):433-9. PubMed ID: 16297088
[TBL] [Abstract][Full Text] [Related]
7. Fluorescence in situ hybridization (FISH) for detection of HER-2/neu amplification in breast cancer: a multicenter portability study.
Persons DL; Bui MM; Lowery MC; Mark HF; Yung JF; Birkmeier JM; Wong EY; Yang SJ; Masood S
Ann Clin Lab Sci; 2000 Jan; 30(1):41-8. PubMed ID: 10678582
[TBL] [Abstract][Full Text] [Related]
8. Her-2/neu expression in breast cancer--A comparison of different diagnostic methods.
Benöhr P; Henkel V; Speer R; Vogel U; Sotlar K; Aydeniz B; Reiser A; Neubauer H; Tabiti K; Wallwiener D; Clare SE; Kurek R
Anticancer Res; 2005; 25(3B):1895-900. PubMed ID: 16158923
[TBL] [Abstract][Full Text] [Related]
9. Comparison of multiplex ligation dependent probe amplification to immunohistochemistry for assessing HER-2/neu amplification in invasive breast cancer.
Purnomosari D; Aryandono T; Setiaji K; Nugraha SB; Pals G; van Diest PJ
Biotech Histochem; 2006; 81(2-3):79-85. PubMed ID: 16908432
[TBL] [Abstract][Full Text] [Related]
10. [Detection of HER-2/neu in breast carcinoma].
Skálová A; Vanĕcek T; Losan F; Papoutsidesová ; Fínek J
Cas Lek Cesk; 2003 Feb; 142(2):93-8. PubMed ID: 12698536
[TBL] [Abstract][Full Text] [Related]
11. Chromogenic in situ hybridization for the detection of HER-2/neu gene amplification in breast cancer with an emphasis on tumors with borderline and low-level amplification: does it measure up to fluorescence in situ hybridization?
Bhargava R; Lal P; Chen B
Am J Clin Pathol; 2005 Feb; 123(2):237-43. PubMed ID: 15842048
[TBL] [Abstract][Full Text] [Related]
12. Real-time reverse transcription-PCR and fluorescence in-situ hybridization are complementary to understand the mechanisms involved in HER-2/neu overexpression in human breast carcinomas.
Vanden Bempt I; Vanhentenrijk V; Drijkoningen M; Wlodarska I; Vandenberghe P; De Wolf-Peeters C
Histopathology; 2005 Apr; 46(4):431-41. PubMed ID: 15810955
[TBL] [Abstract][Full Text] [Related]
13. HER-2/neu amplification by fluorescence in situ hybridization in cytologic samples from distant metastatic sites of breast carcinoma.
Bozzetti C; Personeni N; Nizzoli R; Guazzi A; Flora M; Bassano C; Negri F; Martella E; Naldi N; Franciosi V; Cascinu S
Cancer; 2003 Oct; 99(5):310-5. PubMed ID: 14579298
[TBL] [Abstract][Full Text] [Related]
14. Correlation of her-2/neu gene amplification with other prognostic and predictive factors in female breast carcinoma.
Ariga R; Zarif A; Korasick J; Reddy V; Siziopikou K; Gattuso P
Breast J; 2005; 11(4):278-80. PubMed ID: 15982396
[TBL] [Abstract][Full Text] [Related]
15. Risk of breast cancer according to the status of HER-2/neu oncogene amplification.
Huang WY; Newman B; Millikan RC; Conway K; Hulka BS; Schell MJ; Liu ET
Cancer Epidemiol Biomarkers Prev; 2000 Jan; 9(1):65-71. PubMed ID: 10667465
[TBL] [Abstract][Full Text] [Related]
16. Amplification of c-erbB2 oncogene: a major prognostic indicator in uterine serous papillary carcinoma.
Santin AD; Bellone S; Van Stedum S; Bushen W; Palmieri M; Siegel ER; De Las Casas LE; Roman JJ; Burnett A; Pecorelli S
Cancer; 2005 Oct; 104(7):1391-7. PubMed ID: 16116605
[TBL] [Abstract][Full Text] [Related]
17. [Her-2 gene dosage analysis in human breast cancer by PCR with internal standard].
Matsenko NIu; Kovalenko SP
Mol Gen Mikrobiol Virusol; 2006; (1):34-8. PubMed ID: 16512610
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of HER-2/neu amplification and other biological markers as predictors of response to neoadjuvant anthracycline-based chemotherapy in primary breast cancer: the role of anthracycline dose intensity.
Bozzetti C; Musolino A; Camisa R; Bisagni G; Flora M; Bassano C; Martella E; Lagrasta C; Nizzoli R; Personeni N; Leonardi F; Cocconi G; Ardizzoni A
Am J Clin Oncol; 2006 Apr; 29(2):171-7. PubMed ID: 16601438
[TBL] [Abstract][Full Text] [Related]
19. The effect of chromosome 17 polysomy on HER-2/neu status in breast cancer.
Hyun CL; Lee HE; Kim KS; Kim SW; Kim JH; Choe G; Park SY
J Clin Pathol; 2008 Mar; 61(3):317-21. PubMed ID: 17761736
[TBL] [Abstract][Full Text] [Related]
20. AQUA and FISH analysis of HER-2/neu expression and amplification in a small cell lung carcinoma tissue microarray.
Giltnane JM; Murren JR; Rimm DL; King BL
Histopathology; 2006 Aug; 49(2):161-9. PubMed ID: 16879393
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
